DOI:
10.1055/s-00000005
Aktuelle Rheumatologie
LinksClose Window
References
Poddubnyy D, Sieper J.
What is the best treatment target in axial spondyloarthritis: tumour necrosis factor alpha, interleukin 17, or both?.
Rheumatology (Oxford) 2017;
DOI: 10.1093/rheumatology/kex361. doi:10.1093/rheumatology/kex361
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.